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Emerging treatment strategies in mitochondrial 
disorders
M. Mancuso
Department of Neuroscience, University of Pisa, Italy
Mitochondrial disorders (MDs) are caused by impairment 
of the mitochondrial electron transport chain (ETC). The ETC 
is needed for oxidative phosphorylation, which provides the cell 
with the most efficient energy outcome in terms of ATP produc-
tion. One of the pathogenic mechanisms of MDs is the genera-
tion of reactive oxygen species.
Potential  pharmacological  approaches  for  MDs  include 
ETC  cofactors  (i.e.,  Coenzyme  Q10)  and  other  metabolites 
(i.e., carnitine), antioxidants, neuroprotective drugs (i.e., tetra-
cyclines), bezafibrate (an activator of PGC-1alpha). Controlled 
trials in large cohorts of patients are still needed, because ther-
apy for mitochondrial diseases remains inadequate and mostly 
symptomatic. It will be important to develop a better under-
standing of the role of oxidative stress, since it may lead to the 
development of more effective treatment strategies.
I-6
Pharmacological strategies for Muscular 
Dystrophies. Review of the literature  
and personal data
L. Politano
Cardiomyology and Medical Genetics, Second University of Naples, 
Italy
Although Duchenne Muscular Dystrophy (DMD) has been 
described 175 years ago, therapies for DMD remain supportive 
rather than curative. Gene- and cell-based therapies designed 
to  replace  the  missing  gene  and/or  dystrophin  protein  have 
achieved varying and controversial degrees of success. Three 
different  therapeutic  approaches  are  currently  under  study: 
1. Gene therapy; 2. Cellular therapy; 3. Pharmacological ther-
apy. The latter will be examined into the three fundamental as-
pects: 1. Utrophin over-expression; 2. Dystrophin re-expression; 
3. Reversal of dystrophic phenotype.
1.  Utrophin  over-expression.  Recent  developments  in  un-
derstanding the regulatory pathways that govern utrophin 
expression,  stimulated  studies  using  activators  of  these 
pathways to alleviate the dystrophic symptoms in DMD 
animal models. Drugs used to this aim are: Interleukin 6, 
Agrin, Heregulin, Calcineurin. All these drugs are able to 
induce overexpression of the sarcolemmal utrophin in vitro 
and in neonatal mdx skeletal muscles. The results of these 
preclinical studies are promising and stimulate to imple-
ment appropriate utrophin-based drug therapies for DMD 
patients.
2.  Dystrophin re-expression can be achieved by drug ther-
apy  –  aminoglycosides,  antisense  strategy  and  chimera-
plasty – or by cell therapy – myoblasts and stem cells – or 
by  gene  therapy. Aminoglycosides  have  been  proven  to 
cause an extensive misreading of the RNA code, allowing 
the insertion of alternative amino acids at the site of the 
mutated codon. Although it is now considered a therapeutic 
strategy for DMD caused by point-mutations, unfortunate-
ly it is applicable to only 1% of DMD patients.
3.  Reversal of dystrophic phenotype can be achieved by the 
use of corticosteroids. The two main classes of steroids 
used are prednisone or prednisolone and deflazacort (DFZ). 
They are probably equally effective in stabilizing muscle 
strength but may have different side-effect profiles. The ex-
act mechanism by which steroids slow the dystrophic proc-
ess is yet under investigation. Corticosteroids have been 
found to stabilize or improve muscle strength in boys with 
DMD and to have beneficial effects on the different aspects 
of DMD, such as walking time prolongation, development 
of scoliosis, development of respiratory insufficiency and 
development of cardiac involvement. A systematic review 
of the Cochrane database and the personal experience on 
more  than  200  DMD  patients  treated  with  DFZ  for  20 
years, let us to conclude that long term steroid therapy is 
able to prolong ambulation by 2 to 5 years, reduce the need 
for spinal stabilization surgery, improve cardiopulmonary 
function, delay the need for non invasive nasal ventilation 
and finally increase survival and quality of life of patients 
with Duchenne muscular dystrophy.
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Autoimmune Inflammatory Myopathies: 
Summary on Pathogenesis and Therapies
M. Dalakas
Neuroimmunology Unit, Department of Pathophysiology, University of 
Athens Medical School, Athens, Greece
The most common autoimmune inflammatory myopathies 
include Polymyositis (PM), Dermatomyositis (DM), Necrotiz-
ing Autoimmune Myositis (NAM) and Inclusion Body Myositis 
(IBM). Polymyositis still remains an uncommon but frequently 
misdiagnosed disorder. NAM, IBM, and inflammatory dystro-
phies are the myopathies most often misdiagnosed as PM. The 
presence of MHC-1/CD8 complex remains the most useful im-
munopathologic marker because it reliably distinguishes, most 
of the times, the antigen-driven inflammatory cells that charac-
terize PM and IBM from the non-specific, secondary inflam-
mation seen in dystrophies, and from the non-MHC-I, macro-
phage-mediated process, seen in NAM. In PM and IBM, the 
co-stimulatory molecules ICOS/ICOS-L and PD-L1 are strong-
ly upregulated, indicating an immunological synapse formation 
between cytotoxic T cells and muscle fibers.
In s-IBM, the inflammatory cells invade non-vacuolated 
fibers while the vacuolated fibers are not invaded by T cells im-
plying two independent processes: a primary immune process 
with antigen driven T cells identical to PM, and a degenerative 
process in which β-amyloid and related proteins may participate 
in vacuolar degeneration. An interrelationship between inflam-
mation and amyloid-related or stressor proteins is the most ex-
citing new observation with potential therapeutic implications.
DM is a complement-mediated microangiopathy affecting 
skin and muscles; the role of alpha-interferon-related molecules 
seem to be secondary events. NAM is a histologically distinct 
myopathy of acute/subacute onset that can be associated with 
cancer, viral infections, autoimmunity, or statins. Whether cer-154
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tain antibodies play a role by recruiting macrophages to the 
muscle in an ADCC process, remains unclear.
In uncontrolled studies, PM and DM respond to prednisone 
to some degree and for some period of time; adding an immuno-
suppressive drug (Azathioprine, Cyclosporine, Mycophenolate, 
Methotrexate) may have a steroid-sparing effect but their benefit 
is uncertain. In contrast, IBM is resistant to most of these thera-
pies, most times. Controlled studies have shown that IVIg is 
effective and safe for the treatment of DM. The clinical benefit, 
which can be impressive in patients with early disease, is associ-
ated with improvement in the muscle cytoarchitecture and reso-
lution of the aberrant immunopathological parameters, includ-
ing interception of complement activation and downregulation 
of ICAM-I, VCAM, TGF-β, MHC-I and various immunoregu-
latory and structural genes. IVIg seems to be also effective in 
patients with PM but offers transient help to a small number of 
patients with IBM.
New agents currently on the market may be promising new 
therapies for the treatment of inflammatory myopathies. Among 
them  include  the  monoclonal  antibodies  or  fusion  proteins 
against:  a)  molecules  associated  with  T-cell-signaling  path-
ways,  such  as  the  anti-CD52  (CAMPATH),  anti-LFA/ICAM 
(Leukocyte  Functional Antigen/  Intracellular Adhesion  Mol-
ecule), and anti-IL2 receptor (IL2-receptor antagonist). Further, 
two cytophillin-binding drugs, Tacrolimus and Rapamycin, that 
prevent the IL2-induced T cell proliferation or transcription, 
may be candidate agents for certain conditions; b) B cells using 
the monoclonal antibody directed against CD20, expressed on 
B cells (Rituximab) or the humanized version Occrelizumab; 
agents against B-cell growth factors, such as BAFF and APRIL 
are in the offing; c) Complement C5 (Eculizumab), which might 
be appropriate for some complement-mediated disorders like 
DM or NAM; d) cytokines, especially agents against TNF-α, 
IL1 or IL1β; and e) Cellular Adhesion and T cell transmigration 
molecules. Such agents include Natalizumab directed against 
a4β1 integrin (VLA4) on lymphocytes, a drug approved for 
multiple  sclerosis,  and  Fingolimod,  an  anti-T-cell-migration 
agent that traps lymphocytes in the lymphoid organs.
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Muscle maturation and early pathogenic 
findings in spinal muscular atrophy: any clues 
for therapy?
E. Tizzano
Department  of  Genetics  and  Research  Institute,  Hospital  Sant  Pau, 
Barcelona, Spain; and CIBERER U-705, Barcelona, Spain
Spinal muscular atrophy (SMA) is an autosomal recessive 
disorder that affects motor neurons. It is caused by mutations 
in the survival motor neuron gene 1 (SMN1). The SMN2 gene, 
which is the highly homologous SMN1 copy that is present in 
all patients, is unable to prevent the disease. SMA patients can 
be classified into four groups based on age at onset and acquired 
milestones (type I or severe acute disease, with onset before 6 
months; type II, before 18 months; type III, after 18 months and 
type IV, in adult life). The explanation for the neuromuscular 
phenotype in SMA is to assume that insufficient SMN protein 
causes motor neuron dysfunction and death, and that muscle at-
rophy is a consequence of denervation. However, investigation 
is ongoing to ascertain whether muscle, neuromuscular junc-
tions, or motor neurons alone are the critical target tissue in 
SMA. The neuropathologic description of SMA comes largely 
from postnatal necropsy samples, which describe the end-stage 
of the disease. The human developmental period appears to play 
an essential role in SMA pathogenesis. With the exception of 
severe congenital SMA (type 0), varying age at onset in the 
four SMA types provides evidence of a latency period without 
clear manifestations in most SMA patients. Given that studies 
of patients’ preclinical status are lacking, the main objective of 
our work is to study SMA during development to gain insight 
into the mechanism of disease in the prenatal and presympto-
matic  stage.  Prenatal  SMN  tests  performed  at  around  11-13 
weeks allowed us to identify fetuses predicted to develop SMA 
in families with a previous patient affected by type I disease. 
SMA fetuses were collected from therapeutic abortions after 
confirmation of a homozygous deletion of exon 7 and 8 of the 
SMN gene by chorionic villi DNA analysis. In these samples we 
systematically studied histology, cell death and gene and protein 
expression in spinal cord and muscle, the key tissues involved 
in the disease. The study of terminal peripheral nerves and neu-
romuscular junctions identify possible links between the two 
tissues in the pathogenesis of the disease. By confocal and elec-
tron microscopy we observed a variable degree of changes in 
the acetylcholine receptors clustering, presynaptic retention of 
vesicles and terminal nerve degeneration in the motor endplates 
of  fetuses  with  severe  SMA.  Furthermore,  ultrasound  fetal 
movements were investigated at these stages. At the gestational 
age examined, we did not observe a qualitative early limitation 
of movements in fetuses with SMA. Our results support the 
view of SMA as a developmental disorder and the hypothesis 
that motor neurons, terminal peripheral nerves, neuromuscular 
junctions and skeletal muscle may play all together a role in the 
pathology of SMA. These studies may help to define therapeutic 
targets and delineate a possible early intervention in SMA.
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Opportunities and challenges of pharmaceutical 
research and development today
L. Middleton
Not arrived
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Pathogenesis of muscle degeneration  
in periodic paralyses and DMD
F. Lehmann-Horn, M.A. Weber, A. Nagel, K. Jurkat-Rott
Neurophysiology, Ulm University, Ulm, Germany
Mutations in Cav1.1 and Nav1.4 channels cause hypokale-
mic periodic paralysis, a dominantly inherited muscle disorder 
characterized  by  episodic  weakness  and  chronic  progressive 
weakness. In-vivo 23Na magnetic resonance imaging (MRI), 
fat-suppressed 1H-MRI (STIR), and force assessment were per-
formed to determine intramuscular Na+ load, edema, and mus-
cle strength in patients under different conditions. Membrane 